PFEPfizer Inc.
Pfizer Inc. (PFE) sells prescription drugs, vaccines, and biologics, with a broad portfolio spanning oncology, immunology, and rare diseases. The next catalyst is Nov 3, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to deliver revenue growth and guide on the progress of its key therapies. The earnings report will also provide clarity on the impact of patent expirations and the performance of its newer, more profitable products.
- Revenue fell 44.5% YoY in 2022, reflecting the impact of patent cliffs and generic competition.
- Free cash flow remains robust at $9.80B TTM, with a net margin of 8.9% and a debt-to-equity ratio of 0.08x.
- Shareholders’ equity stands at $86.48B, with a recent dividend declaration of $0.43 per share.
The Read
Pfizer's stock rallied on strong Q4 2025 earnings and operational growth, dipped slightly on neutral Q1 2026 results but found support from positive trial data and patent extensions, held steady amid mixed oncology updates, fell below the bear floor on Q2 earnings but rebounded sharply on cost realignment and bullish clinical strategy updates.
The schedule
- Tue3Nov
Earnings report and guidance for Q3 2026, with potential updates on drug pipeline and cost restructuring.
- Wed4Nov
- Wed3Feb
- Thu6May
Past
- Thu15Oct
Actual outcome: Bull · $29.43 at outcome
Stock fell 4.4% from event to outcome date, aligning with the bull trajectory.
Stock fell 4.4% from event to outcome date, aligning with the bull trajectory.
- Tue15Sep
Actual outcome: Bull · $27.60 at outcome
Price reached or exceeded bull target ($28.50) at outcome date.
Price reached or exceeded bull target ($28.50) at outcome date.
- Fri21Aug
Actual outcome: Bull · $27.97 at outcome
Pfizer provided an update on its clinical strategy for berobenatide, its once-monthly GLP-1 obesity therapy aimed at capturing market share in the weight-loss space. Although the stock traded flat immediately following the event, shares held their ground near the bull target, bolstered by optimistic Wall Street price targets, heavy institutional buying, and confidence in the company's broader pipeline and dividend yield.
- Wed5Aug
Actual outcome: Bull · $27.05 at outcome
Stock rose 6.2% from event to outcome date, aligning with the bull trajectory.
- Sat30May
Actual outcome: Mixed · $26.04 at outcome
Pfizer's stock experienced a muted reaction, falling just 0.5% during the outcome window following its ASCO oncology portfolio update. While the company highlighted its Seagen cancer data, investor focus was split by subsequent pipeline developments, including positive Phase 2b results for its monthly GLP-1 obesity therapy berobenatide and an expanded FDA approval for its hemophilia drug HYMPAVZI. The combination of these clinical updates resulted in flat price action, leaving the stock hovering between its bull and bear targets.
- Thu30Apr
Actual outcome: Mixed · $26.48 at outcome
Pfizer’s Q1 EPS came in exactly in line with estimates at -$0.29, so there was no true earnings beat or miss. The stock also had offsetting catalyst news: ELREXFIO reported positive late-stage trial data and Pfizer reached VYNDAMAX settlement agreements that extend U.S. patent protection to 2031, which helped support sentiment even as the earnings report itself was essentially neutral.
- Tue3Feb
Actual outcome: Bull · $27.22 at outcome
Pfizer delivered a significant Q4 EPS beat ($0.66 actual vs $0.567 estimate), which, combined with confirmation of core business resilience, triggered a relief rally. The stock moved higher because the results provided the 'less bad' outlook investors sought, with the non-COVID portfolio showing 6% operational growth and cost savings initiatives remaining on track. This fundamental strength drove the price past the $27.00 bull target, confirming the bull scenario.
